Side effects · updated 2026-08-24

Tirzepatide Side Effects: The Hair-Loss Question, the GI Adjustment, and What’s Actually Serious

By the Affordable GLP-1 Providers desk · label and trial figures human-verified before launch per our editorial policy · not medical advice

Tirzepatide’s tolerability data looks like semaglutide’s with the volume turned to dose: the GI curve climbs with the milligrams, two label notes are genuinely its own, and the hair question gets the same honest answer.

The hair-loss question at tirzepatide’s magnitude

Zepbound’s label lists hair loss around 4–5% versus ~1% placebo [verify exact figure] — the highest in the class, tracking the largest average weight loss in the class. The mechanism reads as telogen effluvium from loss velocity, not follicle toxicity: onset a few months into rapid loss, diffuse rather than patchy, resolving over months as weight stabilizes. Iron, thyroid, and zinc labs are worth running when shedding is heavy; drug discontinuation is rarely the first move.

The contraception note that hides in plain sight

Tirzepatide’s label uniquely advises that delayed gastric emptying may reduce oral-contraceptive absorption — recommending a switch to a non-oral method or added barrier protection for 4 weeks after initiation and after each dose escalation [verify current wording]. Given how many escalations a full titration contains, this is a standing instruction for months, and telehealth intakes routinely fail to mention it.

The heart-rate line on your wearable

A small mean increase in resting heart rate — typically low single digits of bpm — is documented. It is mostly a curiosity, occasionally a conversation (arrhythmia history, stimulant use), and a good example of a side effect wearables surface before symptoms would.

Injection-site and the everyday layer

Injection-site reactions run somewhat higher than semaglutide’s but remain minor and rotate away. Burping with a sulfurous edge, early fullness, reflux at night after late meals, and vivid food aversions round out the everyday layer — all meal-manageable, all fading with time at held doses for most.

Where the dual mechanism does and doesn’t show up

Adding GIP agonism changed the efficacy curve more than the safety one: the serious list — boxed warning, pancreatitis, gallbladder, dehydration-kidney, hypoglycemia in combination — is the class list, unchanged. The practical difference people feel is simply dose: more milligrams available means more room for the GI curve to climb if titration outruns tolerance.

The tirzepatide side-effect profile, with numbers

In SURMOUNT-1, nausea ran roughly 25–33% depending on dose, diarrhea about 19–23%, vomiting about 8–13%, and constipation about 11–17% — meaningfully dose-dependent, mostly mild-to-moderate, and concentrated during escalation [verify exact label percentages]. Discontinuation for adverse events ran in the mid-single digits.

Two tirzepatide-specific label notes deserve more attention than they get. First, delayed gastric emptying can reduce the absorption of oral contraceptives: the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation [verify current label wording]. Second, a small average increase in resting heart rate is documented — usually a few beats per minute, worth knowing if you track a wearable.

The management playbook mirrors the class: smaller, slower meals; protein early; fluids replaced aggressively on rough days; trigger foods (fried, fatty, very sweet, carbonated) shifted away from dose day; and titration slowed rather than toughed through. Constipation responds to fluid, fiber added gradually, and movement; persistent versions deserve a clinician conversation rather than escalating laxatives.

Serious-but-rarer items — pancreatitis, gallbladder disease, kidney injury from dehydration, hypersensitivity, and the boxed-warning thyroid contraindications — sit in the safety box below, where they belong on every one of these pages.

The management playbook, week by week

Before each escalation: stock the boring kit — bland staples, oral fluids you’ll actually drink, and a plan that puts the first 48–72 hours after a step-up on your calendar’s easiest days (most people dose the night before their least demanding stretch). During the noisy window: small meals eaten slowly, fat and sugar postponed, fluids treated as a scheduled task — two to three liters across the day — because dehydration is the on-ramp to the only common serious complication (kidney injury) that good habits reliably prevent. Ask your prescriber in advance what anti-nausea options they want you to use, so a rough night doesn’t become an improvised one.

Keep a two-line diary: date/dose, and symptoms with times. Escalation-linked symptoms that fade on a held dose are the expected pattern; anything persistent on a stable dose, or severe at any time, breaks the pattern — and that one-page log turns a vague telehealth visit into a precise one. Route problems to the right door: routine titration questions → your prescribing program; new medications, procedures, anesthesia → tell every clinician you take a GLP-1; the emergency list (severe persistent abdominal pain, uncontrolled vomiting, allergic-reaction signs, severe hypoglycemia symptoms, sudden vision change) → emergency care now, program later.

Report what you experience: to your prescriber and pharmacist first, and to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch) — especially for compounded products, where adverse-event reporting is one of the few feedback loops that exists. And two do-nots that cause outsized harm: never double a missed dose, and never adjust insulin or sulfonylureas yourself because appetite fell — that conversation belongs to the clinician who prescribed them, ideally before your first GLP-1 injection.

Mind the interaction seams. Slowed gastric emptying can shift how oral medications absorb — the documented flags include oral contraceptives on tirzepatide (backup for four weeks after initiation and each escalation [verify label]) and tighter glucose monitoring on insulin or sulfonylureas — so walk your full medication list past the prescriber and pharmacist rather than assuming. Alcohol overlaps the same real estate: additive GI effects, hypoglycemia risk with secretagogues, and an independent pancreatitis association that matters on a drug class already carrying the warning.

The bottom line

Tirzepatide Side Effects is a topic where the label, the trials, and the marketing routinely tell three different stories. The version above sticks to the first two, flags what still needs verification, and leaves the clinical decisions where they belong — with a prescriber who knows your history. When you’re ready to compare what any of this costs in practice, the price index carries every price we track with its source and its date.

Questions worth bringing to your prescriber

Walk in with these and the visit gets better. Given my history, which items on the serious list matter most for me? What anti-nausea plan do you want me on before the first escalation, not after a bad night? Which of my current medications need adjusting — especially insulin, sulfonylureas, or anything absorption-sensitive? What symptoms do you want reported to you versus straight to urgent care? At what point would we hold a dose, step down, or stop — what’s our exit criteria? Anything upcoming — surgery, imaging, dental sedation — where the anesthesia team needs to know? Bring your two-line diary; the pattern in it will answer half of these before you ask.

How to read this article — and everything else on this site

House rules, so you can audit us: label claims cite labels, trial numbers cite the named trial, and a bracketed [verify] marks a figure our desk re-checks against the current source before each publication cycle rather than trusting memory. Dates matter as much as numbers — labels get revised, prices move — so treat anything undated (here or anywhere) as a rumor with good typography. Nothing above transfers to compounded copies: they are pharmacy preparations that are not FDA-approved, and a trial that tested the brand tested the brand. If you catch an error, [email protected] reaches a human with a 72-hour target; the corrections log shows we mean it.

Two more reading habits pay for themselves. First, separate frequency from severity: a 40% side effect that fades in a week and a 1% one that ends up in an emergency department are different kinds of facts, and sentences that blur them are selling something. Second, notice denominators — “in trials” means the approved product at protocol doses in monitored adults, which is the strongest evidence available and still not a promise about a different product, a different dose, or you.

Frequently asked questions

Related: Important safety information · Protein & water targets · Site FAQ · The full price index